|
||||||
| Home |
| Find a Clinical Trial |
| Clinical Trial FAQs |
| About Informed Consent |
| Clinical Trials Glossary |
| Medical Research Areas |
| Clinical Trial Resources |
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
 |
|
|
|
|||
|
Novartis Clinical
Trials provides information about research studies recruiting
within the U.S. Visit ClinicalTrials.gov, a registry of federally and privately supported clinical trial for more information regarding clinical trials outside of the U.S. |
|
|
Find a Clinical Trial
High Blood Pressure
Also known as hypertension (hi-per-TEN-shun), this condition usually causes no symptoms, unless the pressure gets extremely high; it's therefore often called the "silent killer". Over time the elevated pressure causes damage to the blood vessels and to the organs the vessels supply with blood. This can result in stroke, heart attack, kidney failure, heart failure and damage to the eye, called retinopathy.
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Hypertension Study CSPP100A2409
The purpose of this clinical research trial is to find out if the drug aliskiren hydrochlorothiazide (Tekturna® HCT) compared to amlodipine (Norvasc®) alone is safe and will effectively lower blood pressure in participants who have diabetes and stage 2 systolic hypertension (which occurs when systolic blood pressure is greater than or equal to 160 mm Hg or less than 200 mm Hg).
Both medicines are approved by the US Food and Drug Administration (FDA) for the treatment of people with high blood pressure.
Trial phase: Phase 4 Participation Duration: Participants will be required to visit the study center a maximum of 8 times over a duration of 8 weeks. Each visit will take about 1-2 hours. Protocol Number: CSPP100A2409 Hypertension Study CSPP100A2410
The purpose of this clinical research trial is to find out if a single drug (aliskiren) or a combination of 2 drugs (aliskiren hydrochlorothiazide) will control high blood pressure better, in patients high blood pressure and metabolic syndrome.
Both aliskiren hydrochlorothiazide and aliskiren are approved by the US Food and Drug Administration (FDA) for the treatment of people with high blood pressure.
Trial phase: Phase 4 Participation Duration: Participants will be required to visit the study center between 6 to 8 times over a duration of 12 weeks. Protocol Number: CSPP100A2410
Hypertension Study CSPV100AUS02
The purpose of this clinical study is to find out if taking a combination of the drugs, aliskiren and valsartan, is more effective in lowering blood pressure than taking the individual drug alone. Participants must be over 18 years old, have high blood pressure and type 2 diabetes.
The combination of aliskiren and valsartan is investigational, which means that it is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA). Individually, aliskiren and valsartan are both approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Trial phase: Phase 4 Participation Duration: Participants will be required to visit the study center between 5 to 8 times over a duration of 9 to 12 weeks. Protocol Number: CSPV100AUS02 |